AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02554435 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
Study NCT00832715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Description: Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
Study NCT04738045 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.
Study NCT04738045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ Ritonavir and Remdesivir combination
Description: Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days
Study NCT00091390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose brachytherapy boost
Description: 19 Gy in two fractions (on day of placement and 6-24 hours later) before or after external beam radiotherapy, such that all study treatment occurs within 8 weeks.
Study NCT00091390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: 45 Gy as 1.8 Gy five days a week for five weeks.
Study NCT01322607 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: High-intensity Treadmill Exercise
Description: High-intensity treadmill walking program
Study NCT01322607 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Low-intensity Lifestyle Intervention
Description: A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
Study NCT02289755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177
Description: ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
Study NCT00739297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: montelukast
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
Study NCT00739297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: montelukast
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
Study NCT00739297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: 5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
Study NCT01858428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter
Description: The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
Study NCT01858428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EverCross Percutaneous Transluminal Balloon Catheter
Description: The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
Study NCT03332004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: 0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
Study NCT02335450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
Study NCT02335450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband physical activity monitor
Description: The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
Study NCT00758303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose TRIA-662
Description: One Capsule 3 times a day
Study NCT00758303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose TRIA-662
Description: 3 Capsules 3 times daily
Study NCT01151618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respironics Synchrony ventilator (Non Invasive Ventilation)
Description: Non Invasive Ventilation using forced oscillation technique (FOT)
Study NCT02480634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Description: Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
Study NCT02480634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
Study NCT02480634 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: High dose：30Gy/10f Low dose：15Gy/5f
Study NCT02480634 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: High dose：30Gy/10f Low dose：15Gy/5f
Study NCT00210639 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
Study NCT04175587 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
Description: Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
Study NCT04175587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
Description: Randomization is done centrally according to trial centers Eligible patients are randomly assigned (2:1) to the Treatment Group or the Control Group, with a 24-month follow-up.
Study NCT04621617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Human albumin will be administered by intravenous infusion at a dose of 1.5 gm/kg/week for 2 weeks followed by HA 40 grams every 7days
Study NCT04621617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midodrine
Description: Oral Midodrine will be given at a dose of 7.5 mg three times in a day
Study NCT04621617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy (SMT)
Description: SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Study NCT04621617 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical therapy (SMT)
Description: SMT will include nutritional support, rifaximin, lactulose or lactitol, diuretics, SBP prophylaxis with norfloxacin, restriction of sodium, multivitamins, and other supportive measures as deemed necessary. LVP will be done as needed. Patients on non-selective beta blockers will continue to do so with dose modifications/withdrawal as per Baveno VI guidelines.
Study NCT03202927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEGFILGRASTIM
Description: Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
Study NCT03202927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGFILGRASTIM
Description: Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
Study NCT03248128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI via ELLIPTA DPI
Description: ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
Study NCT00289978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Study NCT00289978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients self-administered a fingolimod placebo capsule orally once daily.
Study NCT01890538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Administration of 100 mg dimenhydrinate intravenous
Study NCT01890538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 g piracetam intravenous
Study NCT00626665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tadalafil
Description: Tablets Tadalafil, 20 mg, alternate days, 6 weeks
Study NCT03709030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: magnetic resonance cholangiopancreatography (MRCP)
Description: magnetic resonance imaging of liver, gall bladder, pancreas
Study NCT02285660 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 4D PET-CT Scan
Study NCT02285660 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study NCT03248128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF via ELLIPTA DPI
Description: ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
Study NCT03153605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common toothpaste
Description: different toothpaste
Study NCT01379313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional I:E ratio
Description: conventional I:E ratio of 1:2 is applied.
Study NCT01379313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 1:1 ratio
Description: I:E ratio of 1:1 is applied.
Study NCT01379313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2:1 group
Description: Inverse I:E ratio of 2:1 is applied.
Study NCT00758303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TRIA-662
Description: Matching Placebo for TRIA-662 taken 3 times a day
Study NCT00784784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral
Description: One dose
Study NCT00784784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 10 mg, OD, for duration of influenza season (10-23 weeks)
Study NCT00221845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE Inhibition
Description: ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
Study NCT00221845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE Inhibition
Description: ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
Study NCT01379313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external PEEP
Description: external positive end-expiratory pressure of 5 cmH2O is applied.
Study NCT03135080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-Term HEAD START Training
Description: The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
Study NCT03135080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
Study NCT03171194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Mesenchymal Stem Cells (MSCs)
Description: Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
Study NCT04384289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nursing care based on the Transitonal Care Model
Description: Nursing care carried out in collaboration with a multidisciplinary team in line with Transitonal Care Model for elderly patients who have undergone open heart surgery
Study NCT04200872 — intervention group
Intervention type: OTHER
Intervention: biological adjuvants
Description: patients with aseptic pseudarthrosis clinically treated with biological adjuvants
Study NCT04200872 — intervention group
Intervention type: OTHER
Intervention: no biological adjuvants
Description: patients with aseptic pseudarthrosis clinically treated without biological adjuvants
Study NCT02004769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
Study NCT02004769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
Study NCT02004769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
Study NCT03522532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amalgam placement
Description: Before the Amg was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study NCT03522532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tetric EvoCeram placement
Description: Before the TEC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study NCT03522532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Beautifil placement
Description: Before the BF was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study NCT03522532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement placement
Description: Before the ZPhC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study NCT03522532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zinc polycarboxylate cement placement
Description: Before the ZPoC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study NCT03486106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be provided via Spotify, which is an Internet streaming music service, and will be played through headphones; this way, no other individual in the operating room will be distracted or influenced by the patient's music selection.
Study NCT03522532 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement placement
Description: Before the GIC was sealed GCF was taken, and then taken again on the 7th and 30th days after the applied treatment.
Study NCT03486106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Headphones
Description: All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
Study NCT03486106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Headphones
Description: All participants will receive noise-cancelling wireless headphones that they will wear in the operating room during the procedure.
Study NCT00221845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intensified Blood Pressure Control
Description: Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
Study NCT00221845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensified Blood Pressure Control
Description: Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
Study NCT02117830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg capsules
Study NCT00221845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add-on Angiotensin Receptor Blockade
Description: In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Study NCT03486106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
Study NCT03486106 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: All participants will receive intravenous doses of propofol; the timing and frequency of the doses will be given when the patient indicates (by squeezing a rubber duckie) that he/she wants sedation medication.
Study NCT00221845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-on Angiotensin Receptor Blockade
Description: In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
Study NCT01182129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine pouch, 2.2 mg, single dose, 30 minutes
Study NCT01182129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Chewing Gum, 4 mg, single dose, 30 minutes
Study NCT03698240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program
Description: The program includes 9 mindfulness-based sessions for children and their parents.
Study NCT02379910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM1030-CREAM or placebo
Study NCT01828099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule.
Study NCT01828099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed was administered at a dose of 500 mg/m\^2 as an intravenous (iv) infusion on Day 1 of each 21-day cycle
Study NCT01713400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
Study NCT01713400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
Study NCT01713400 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tacrolimus (TAC)
Description: Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.